Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;67(5):703-9.
doi: 10.1136/ard.2007.078923. Epub 2007 Sep 24.

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

D Khanna  1 , D J Lovell, E Giannini, P J Clements, P A Merkel, J R Seibold, M Matucci-Cerinic, C P Denton, M D Mayes, V D Steen, J Varga, D E Furst; Scleroderma Clinical Trials Consortium co-authors
Collaborators, Affiliations

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

D Khanna et al. Ann Rheum Dis. 2008 May.

Abstract

Objective: To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc).

Methods: The Scleroderma Clinical Trials Consortium (SCTC) conducted a structured, 3-round Delphi exercise to reach consensus on a core set of measures for clinical trials of SSc. Round 1 asked the SCTC investigators to list items in 11 pre-defined domains (skin, musculoskeletal, cardiac, pulmonary, cardio-pulmonary, gastrointestinal, renal, Raynaud phenomenon and digital ulcers, health-related quality of life and function, global health, and biomarkers) for SSc clinical trials. Round 2 asked respondents to rate the importance of the chosen items and was followed by a meeting, during which the Steering Committee discussed the feasibility, reliability, redundancy and validity of the items. Round 3 sought to obtain broader consensus on the core set measures. Members also voted on items that had data on feasibility but lacked data on reliability and validity, but may still be useful research outcome measures for future trials.

Results: A total of 50 SCTC investigators participated in round 1, providing 212 unique items for the 11 domains. In all, 46 (92%) participants responded in round 2 and rated 177 items. The ratings of 177 items were reviewed by the Steering Committee and 31 items from the 11 domains were judged to be appropriate for inclusion in a 1-year multi-centre clinical trial. In total, 40 SCTC investigators completed round 3 and ranked 30 of 31 items as acceptable for inclusion in the core set. The Steering Committee also proposed 14 items for a research agenda.

Conclusion: Using a Delphi exercise, we have developed a provisional core set of measures for assessment of disease activity and severity in clinical trials of SSc.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Process of choosing core set items. OMERACT, Outcome Measures in Rheumatology Clinical Trials; SC, Steering Committee; SCTC, Scleroderma Clinical Trials Consortium; SSc, scleroderma (systemic sclerosis).
See this image and copyright information in PMC

References

    1. Altman RD, Medsger TA, Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma) Arthritis Rheum. 1991;34:403–413. - PubMed
    1. Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, et al. Health values of patients with systemic sclerosis. Arthritis Rheum. 2007;57:86–93. - PubMed
    1. Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, et al. Development of the Scleroderma Gastrointestinal Tract 1.0 (SSc–GIT 1.0) Quality of Life Instrument. Arthritis Rheum. 2007;57:1280–1286. - PubMed
    1. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995;38:351–360. - PubMed
    1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006;367:1683–1691. - PubMed

Publication types